MX336994B - Compuestos de indolil o indolinil hidroxamato. - Google Patents

Compuestos de indolil o indolinil hidroxamato.

Info

Publication number
MX336994B
MX336994B MX2012011337A MX2012011337A MX336994B MX 336994 B MX336994 B MX 336994B MX 2012011337 A MX2012011337 A MX 2012011337A MX 2012011337 A MX2012011337 A MX 2012011337A MX 336994 B MX336994 B MX 336994B
Authority
MX
Mexico
Prior art keywords
indolyl
hydroxamate compounds
indolinyl hydroxamate
indolinyl
compounds
Prior art date
Application number
MX2012011337A
Other languages
English (en)
Other versions
MX2012011337A (es
Inventor
Ching-Shih Chen
Jing-Píng Liou
Hsing-Jin Liu
Kuo-Sheng Hung
Wen-Ta Chiu
Che-Ming Teng
Pei-Wen Shan
Original Assignee
Univ Taipei Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Taipei Medical filed Critical Univ Taipei Medical
Publication of MX2012011337A publication Critical patent/MX2012011337A/es
Publication of MX336994B publication Critical patent/MX336994B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

En este documento se describen indolil o indolinil hidroxamatos y composiciones farmacéuticas que comprenden los mismos, los cuales muestran actividad de inhibición de histona diacetilasas (HDAC). También se describe un método para tratar el cáncer con estos compuestos.
MX2012011337A 2010-03-29 2011-03-29 Compuestos de indolil o indolinil hidroxamato. MX336994B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31871510P 2010-03-29 2010-03-29
PCT/US2011/030263 WO2011126821A2 (en) 2010-03-29 2011-03-29 Indolyl or indolinyl hydroxamate compounds

Publications (2)

Publication Number Publication Date
MX2012011337A MX2012011337A (es) 2013-02-26
MX336994B true MX336994B (es) 2016-02-09

Family

ID=44710365

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012011337A MX336994B (es) 2010-03-29 2011-03-29 Compuestos de indolil o indolinil hidroxamato.

Country Status (19)

Country Link
US (2) US8846748B2 (es)
EP (1) EP2552887B1 (es)
JP (1) JP5868386B2 (es)
KR (1) KR101854610B1 (es)
CN (1) CN102947268B (es)
AU (1) AU2011238628B2 (es)
BR (1) BR112012024822B8 (es)
CA (1) CA2795085C (es)
CO (1) CO6630142A2 (es)
ES (1) ES2707234T3 (es)
IL (1) IL222170A (es)
MX (1) MX336994B (es)
MY (1) MY172081A (es)
NZ (1) NZ602696A (es)
PL (1) PL2552887T3 (es)
RU (1) RU2584682C2 (es)
SG (1) SG184294A1 (es)
TW (1) TWI429628B (es)
WO (1) WO2011126821A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104080451B (zh) * 2011-09-15 2016-08-24 台北医学大学 吲哚异羟肟酸和吲哚啉异羟肟酸于治疗心脏衰竭或神经损伤的用途
EP2844259A4 (en) 2012-04-30 2015-11-11 Anderson Gaweco MMR MODULATORS AND USES THEREOF
JOP20130213B1 (ar) 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
CA2931345A1 (en) * 2013-11-24 2015-05-28 Taipei Medical University Use of indolyl and idolinyl hydroxamates for treating neurodegenerative disorders or cognitive deficits
JP6726658B2 (ja) * 2014-04-11 2020-07-22 イェン、ユンＹＥＮ，Ｙｕｎ ヒストン脱アセチル化酵素阻害剤
US20150368195A1 (en) * 2014-06-20 2015-12-24 Taipei Medical University Indoline compounds for treatment and/or prevention of inflammation diseases
JP7055017B2 (ja) 2014-09-29 2022-04-15 武田薬品工業株式会社 結晶形の１－（１－メチル－１ｈ－ピラゾール－４－イル）－ｎ－（（１ｒ，５ｓ，７ｓ）－９－メチル－３－オキサ－９－アザビシクロ［３．３．１］ノナン－７－イル）－１ｈ－インドール－３－カルボキサミド
CN107531660A (zh) 2015-03-13 2018-01-02 福马治疗股份有限公司 作为HDAC8抑制剂的α‑肉桂酰胺化合物和组合物
CN105085368B (zh) * 2015-04-23 2017-10-20 华侨大学 一种海参生物碱及其制备方法和应用
US10273246B2 (en) * 2015-05-18 2019-04-30 University Of Utah Research Foundation Methods and compositions of substituted 5H-[1,2,5] oxadiazolo [3′,4′:5,6] pyrazino[2,3-B] indole analogs as inhibitors of β-catenin/T-cell factor protein-protein interactions
JP7302120B2 (ja) 2015-10-27 2023-07-04 タイペイ メディカル ユニバーシティ 線維症疾患の治療及び／又は予防用インドリン誘導体
CN105348169B (zh) * 2015-11-16 2018-03-30 青岛大学 一种组蛋白去乙酰酶抑制剂(e)‑3‑(2‑(1‑(4‑氯苯甲酰基)‑5‑甲氧基‑2‑甲基‑1氢‑吲哚‑3‑基)乙酰氨基)‑n‑羟基丁‑2‑烯酰胺及其制备方法和应用
US20190016680A1 (en) 2016-01-14 2019-01-17 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
WO2020102616A1 (en) * 2018-11-16 2020-05-22 Nimbus Artemis, Inc. Acly inhibitors and uses thereof
CN111610260A (zh) * 2020-04-30 2020-09-01 广州汇标检测技术中心 一种兽药喹烯酮中乙酰甲喹的检测方法
CN112321479B (zh) * 2020-11-04 2022-02-08 吉林大学 一种桑寄生中具有抑菌活性的吲哚-4-甲醛化合物、制备方法及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5239083A (en) 1991-03-11 1993-08-24 Kyowa Hakko Kogyo Co., Ltd. Indole derivatives which inhibit steroid 5α reductase
JPH0578315A (ja) * 1991-03-11 1993-03-30 Kyowa Hakko Kogyo Co Ltd インドール誘導体
ES2159618T3 (es) 1993-11-17 2001-10-16 Kyowa Hakko Kogyo Kk Derivados de propenona.
EP0807105B1 (en) * 1994-10-27 2004-06-16 Fujisawa Pharmaceutical Co., Ltd. Pyridopyrimidones, quinolines and fused n-heretocycles as bradykinin antagonists
US7569724B2 (en) * 2000-09-29 2009-08-04 Topotarget Uk Limited Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
US20020103192A1 (en) * 2000-10-26 2002-08-01 Curtin Michael L. Inhibitors of histone deacetylase
HUP0400343A2 (hu) * 2001-03-29 2004-09-28 Bristol-Myers Squibb Co. Ciklopropil-indol-származékok mint szelektív szerotonin-újrafelvétel inhibitorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
EP1397136A1 (en) 2001-05-25 2004-03-17 Queen's University At Kingston Heterocyclic beta-aminoacids and their use as anti-epileptogenic agents
EP2009064B1 (en) * 2002-07-29 2012-10-24 Mitsubishi Paper Mills Limited Organic dye, photoelectric transducing material, semiconductor electrode, and photoelectric transducing device
EP1735319B1 (en) 2004-03-26 2017-05-03 MethylGene Inc. Inhibitors of histone deacetylase
JP2006169189A (ja) 2004-12-17 2006-06-29 Rengo Co Ltd チョークブルード病抑止剤
WO2006101456A1 (en) * 2005-03-21 2006-09-28 S*Bio Pte Ltd Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors
TW200716545A (en) * 2005-06-10 2007-05-01 Sigma Tau Ind Farmaceuti Indole derivatives having anti-tumor activity
TW200718691A (en) * 2005-06-10 2007-05-16 Sigma Tau Ind Farmaceuti Cinnamic and phenylpropiolic acid derivatives useful as anti-tumour agents
US7732475B2 (en) 2005-07-14 2010-06-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20080234349A1 (en) 2005-09-07 2008-09-25 Jack Lin PPAR active compounds
CA2644809A1 (en) 2006-03-02 2007-09-07 Astellas Pharma Inc. 17 .beta. hsd type 5 inhibitor
WO2007109178A2 (en) * 2006-03-16 2007-09-27 Pharmacyclics, Inc. Indole derivatives as inhibitors of histone deacetylase
WO2008060721A1 (en) * 2006-11-14 2008-05-22 Pharmacyclics, Inc. Uses of selective inhibitors of hdac8 for treatment of t-cell proliferative disorders
US8962674B2 (en) 2006-11-30 2015-02-24 Tokyo Institute Of Technology Curcumin derivative
WO2008095908A1 (en) 2007-02-06 2008-08-14 Novartis Ag 1-benzenesulfonyl-1h-indole derivatives as inhibitors of ccr9 activity
AU2008233553A1 (en) * 2007-03-29 2008-10-09 Daiichi Sankyo Company, Limited Indole derivative having cPLA2 inhibitory activity, use of the same and method for producing the same
FR2928924B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
ES2575873T3 (es) * 2008-04-15 2016-07-01 Pharmacyclics Llc Inhibidores selectivos de histona desacetilasa

Also Published As

Publication number Publication date
US9598364B2 (en) 2017-03-21
WO2011126821A2 (en) 2011-10-13
RU2012141499A (ru) 2014-05-10
US20140364477A1 (en) 2014-12-11
MY172081A (en) 2019-11-13
AU2011238628A1 (en) 2012-11-01
JP5868386B2 (ja) 2016-02-24
CN102947268B (zh) 2017-02-15
CN102947268A (zh) 2013-02-27
CA2795085A1 (en) 2011-10-13
KR101854610B1 (ko) 2018-05-04
JP2013523747A (ja) 2013-06-17
CA2795085C (en) 2019-06-11
WO2011126821A3 (en) 2012-04-19
IL222170A0 (en) 2012-12-02
BR112012024822A2 (pt) 2017-08-08
TWI429628B (zh) 2014-03-11
IL222170A (en) 2015-05-31
ES2707234T3 (es) 2019-04-03
AU2011238628B2 (en) 2016-10-27
MX2012011337A (es) 2013-02-26
US20110245315A1 (en) 2011-10-06
NZ602696A (en) 2015-03-27
US8846748B2 (en) 2014-09-30
BR112012024822B8 (pt) 2021-10-05
SG184294A1 (en) 2012-11-29
EP2552887B1 (en) 2018-10-24
KR20130079372A (ko) 2013-07-10
RU2584682C2 (ru) 2016-05-20
CO6630142A2 (es) 2013-03-01
PL2552887T3 (pl) 2019-05-31
EP2552887A2 (en) 2013-02-06
BR112012024822B1 (pt) 2021-09-08
TW201206883A (en) 2012-02-16
EP2552887A4 (en) 2013-09-04

Similar Documents

Publication Publication Date Title
MX336994B (es) Compuestos de indolil o indolinil hidroxamato.
WO2009129335A3 (en) Selective inhibitors of histone deacetylase
HRP20181647T1 (hr) Novi spojevi koji su selektivni inhibitori histonske deacetilaze i farmaceutski pripravak koji ih sadrži
MX2020009870A (es) Inhibidores de histona desacetilasa.
MX2015003959A (es) Inhibidores de histona demetilasas.
WO2012082436A3 (en) Modulators of histone methyltransferase, and methods of use thereof
EP2573069A3 (en) Inhibitors of histone deacetylase and prodrugs thereof
EP3328844A4 (en) 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
MX2015007205A (es) Inhibidores de la desmetilasa de histona.
PH12016500649A1 (en) Combinations of histone deactylase inhibitors and immunomodulatory drugs
WO2012040499A3 (en) Metabolic inhibitors
MX2017000307A (es) Tratamiento de leucemia con inhibidores de histona deacetilasa.
WO2014035140A3 (en) Compounds and compositions for modulating histone methyltransferase activity
TW200734315A (en) Benzodiazepine and benzopiperazine analog inhibitors of histone deacetylase
WO2011084991A3 (en) Fluorinated hdac inhibitors and uses thereof
WO2011028873A3 (en) Polyisobutylene urethane, urea and urethane/urea copolymers and medical leads containing the same
IL188692A0 (en) Histone deacetylase inhibitors
MX2009011210A (es) Inhibidores de mcl1 de indol 7-no sustituido.
MX2014007969A (es) Hidroxiamidas de ácido cinámico como inhibidores de la histona desacetilasa 8.
WO2009054878A3 (en) Compositions and methods for the treatment of neoplasia
MX2019008302A (es) Inhibidores biciclicos de histona desacetilasa.
ZA201203689B (en) A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a sytoplasmic glycolysis reduction agent
EP2205070A4 (en) N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS INHIBITORS OF HISTONE DEACETYLASE
MX2019007346A (es) Inhibidores de histona deacetilasa.
PH12015500069A1 (en) Histone deacetylase inhibitors and compositions and methods of use thereof

Legal Events

Date Code Title Description
FG Grant or registration